Dr. Bernhard Noll has provided strategic guidance in the area of CMC for pre-clinical and clinical development of therapeutic biopolymers such as oligonucleotides and proteins.
Prior to founding NB|Chem.de Dr. Bernhard Noll has served as CMC Project Manager at ThromboGenics, Belgium (2012) where he supervised CMC activities at external contractor sitesand contributed to the company's successful first BLA submission.
He has served as Associate Director CMC, at Roche Kulmbach GmbH, Germany (2008 - 2011), where he was responsible for analytical development and quality control of oligonucleotide drug substance (API) and formulated drug product (DP), playing a leading role in the IND preparation of Roche's first siRNA therapeutic.
He held positions of increasing responsibilities at Coley Pharmaceutical GmbH/Pfizer in Düsseldorf, Germany (1998 - 2008), where he helped thge company to evolve from a small start-up to a major player in the field of oligonucleotide therapeutics.
Dr. Bernhard Noll obtained his diploma in Chemistry at the Technische Universität Darmstadt in 1993 and received his Ph.D. in Biochemistry and Immunology at the University of Mainz in 1997.
He has regularly published the results of his work in peer-reviewed journals, presented at international conferences and contributed to guidelines and textbooks.